BioViva USA has been granted U.S. Patent No. 12,653,907 covering therapeutic methods that combine human telomerase reverse transcriptase (hTERT) with Follistatin-344, delivered via viral vectors including adeno-associated virus. The issued claims address telomere length, muscle mass and blood-glucose regulation — three endpoints that track closely with biological aging. The company states the technologies remain investigational and that patent issuance is not regulatory approval.
Key Points
- Patent covers combined hTERT and Follistatin-344 gene therapy methods
- Claims target telomere length, muscle mass, blood-glucose levels
- Delivery includes AAV vectors; technologies remain investigational, unapproved
Longevity Analysis
Pairing telomerase with a myostatin inhibitor addresses replicative capacity and tissue rebuilding at the same time, acknowledging that cellular renewal without preserved muscle and glucose handling produces limited functional gain. Muscle mass and glycemic control are among the most reliable predictors of healthspan, and their inclusion as patent endpoints signals a shift from single-pathway intervention toward coordinated support of regeneration, metabolic function and structural integrity. Intellectual property protection precedes clinical evidence, however, and the practical question remains whether durable vector-delivered expression can be achieved without compromising immune tolerance or proliferative control.
Original published by LT Wire, by LT Staff.